T. Rowe Price Investment Management
RAPT

T. Rowe Price Investment Management’s RAPT Therapeutics RAPT Stock Holding History

T. Rowe Price Investment Management’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-159,733
Closed -$31.8M – 652
2023
Q4 		$31.8M Buy
159,733
+3,246
+2% +$402K 0.02% 447
2023
Q3 		$20.8M Buy
156,487
+1,164
+0.7% +$190K 0.01% 472
2023
Q2 		$23.2M Buy
155,323
+1,350
+0.9% +$210K 0.02% 463
2023
Q1 		$22.6M Sell
153,973
-1,994
-1% -$403K 0.02% 459
2022
Q4 		$24.7M Buy
155,967
+383
+0.2% +$61.3K 0.02% 436
2022
Q3 		$29.9M Buy
+155,584
New +$29.4M 0.02% 406

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

T. Rowe Price Investment Management's RAPT Position: Q1 2024 in Review

T. Rowe Price Investment Management sold out of RAPT Therapeutics (RAPT) in Q1 2024, closing a stake of 159,733 shares — an estimated $31.8M sold.

T. Rowe Price Investment Management first reported a position in RAPT in Q3 2022 and held it in 6 quarters. The position peaked at $31.8M in Q4 2023. 121 funds tracked by Wall St. Rank hold RAPT as of Q1 2024.

  • T. Rowe Price Investment Management reported no remaining RAPT Therapeutics position as of Q1 2024 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 159,733 RAPT Therapeutics shares in Q1 2024, an estimated $31.8M.
  • T. Rowe Price Investment Management first reported a position in RAPT Therapeutics in Q3 2022 and held it in 6 quarters.
  • T. Rowe Price Investment Management's RAPT Therapeutics position peaked at $31.8M in Q4 2023.
  • 121 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2024.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2024, filed 15 May 2024.